RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer

References

• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin.55(1), 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Kouvaraki MA, Shapiro SE, Perrier ND et al. RET proto-oncogene, a review and update of genotype–phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid15(6), 531–544 (2005).
   PubMed Web of Science ®Google Scholar
• Block MA, Jackson CE, Greenawald KA, Yott JB, Tashjian AH Jr. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications. Arch. Surg.115(2), 142–148 (1980).
   PubMedGoogle Scholar
• Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab.86(12), 5658–5671 (2001).
   PubMed Web of Science ®Google Scholar
• Farndon JR, Leight GS, Dilley WG et al. Familial medullary thyroid carcinoma without associated endocrinopathies, a distinct clinical entity. Br. J. Surg.73(4), 278–281 (1986).
   PubMed Web of Science ®Google Scholar
• Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N. Engl. J. Med.353(11), 1105–1113 (2005).
   PubMedGoogle Scholar
• Ponder BA, Ponder MA, Coffey R et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet1(8582), 397–401 (1988).
   PubMed Web of Science ®Google Scholar
• Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma, clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer88(5), 1139–1148 (2000).
   PubMed Web of Science ®Google Scholar
• Quayle FJ, Moley JF. Medullary thyroid carcinoma, including MEN 2A and MEN 2B syndromes. J. Surg. Oncol.89(3), 122–129 (2005).
   PubMedGoogle Scholar
• Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP 3rd. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer73(2), 432–436 (1994).
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo M, Bajetta E, Bochicchio AM et al. A Phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (ITMO) Group. Ann. Oncol.6(1), 77–79 (1995).
   PubMed Web of Science ®Google Scholar
• Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d’Etude des Tumeurs a Calcitonine (GETC). Br. J. Cancer83(6), 715–718 (2000).
   PubMed Web of Science ®Google Scholar
• Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer, analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid6(4), 305–310 (1996).
   PubMed Web of Science ®Google Scholar
• Modigliani E, Cohen R, Campos JM et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma, results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin. Endocrinol.48(3), 265–273 (1998).
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US 1985–1995 Cancer83(12), 2638–2648 (1998).
   PubMed Web of Science ®Google Scholar
• Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma, demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer107(9), 2134–2142 (2006).
   PubMed Web of Science ®Google Scholar
• Donis-Keller H, Dou S, Chi D et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet.2(7), 851–856 (1993).
   PubMed Web of Science ®Google Scholar
• Mulligan LM, Kwok JB, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature363(6428), 458–460 (1993).
   PubMed Web of Science ®Google Scholar
• Carlson KM, Dou S, Chi D et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl Acad. Sci. USA91(4), 1579–1583 (1994).
   PubMed Web of Science ®Google Scholar
• Wells SA Jr, Chi DD, Toshima K et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg.220(3), 237–247 (1994).
   PubMedGoogle Scholar
• Skinner MA. Management of hereditary thyroid cancer in children. Surg. Oncol.12(2), 101–104 (2003).
   PubMedGoogle Scholar
• Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell42(2), 581–588 (1985).
   PubMed Web of Science ®Google Scholar
• Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev.16(4–5), 441–467 (2005).
   PubMed Web of Science ®Google Scholar
• Drosten M, Putzer BM. Mechanisms of disease, cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat. Clin. Pract. Oncol.3(10), 564–574 (2006).
   PubMedGoogle Scholar
• Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett.204(2), 197–211 (2004).
   PubMed Web of Science ®Google Scholar
• Schuringa JJ, Wojtachnio K, Hagens W et al. MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene20(38), 5350–5358 (2001).
   PubMedGoogle Scholar
• Ball DW. Medullary thyroid cancer, therapeutic targets and molecular markers. Curr. Opin. Oncol.19(1), 18–23 (2007).
   PubMed Web of Science ®Google Scholar
• Schuchardt A, D’Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature367(6461), 380–383 (1994).
   PubMed Web of Science ®Google Scholar
• Eng C, Clayton D, Schuffenecker I et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA276(19), 1575–1579 (1996).
   PubMed Web of Science ®Google Scholar
• Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell Biol.15(3), 1613–1619 (1995).
   PubMed Web of Science ®Google Scholar
• Santoro M, Carlomagno F, Romano A et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science267(5196), 381–383 (1995).
   PubMed Web of Science ®Google Scholar
• Salvatore D, Melillo RM, Monaco C et al. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Res.61(4), 1426–1431 (2001).
   PubMedGoogle Scholar
• Ren R. Mechanisms of BCR-ABL in the pathogenesis of CML. Nature Rev. Cancer5(3) 172–183 (2005).
   PubMed Web of Science ®Google Scholar
• Cuccuru G, Lanzi C, Cassinelli G et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J. Natl Cancer Inst.96(13), 1006–1014 (2004).
   PubMedGoogle Scholar
• Strock CJ, Park JI, Rosen DM et al. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J. Clin. Endocrinol. Metab.91(1), 79–84 (2006).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Heymach JV, O’Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474), an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin. Investig. Drugs16(2), 239–249 (2007).
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res.62(24), 7284–7290 (2002).
   PubMed Web of Science ®Google Scholar
• de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ et al. A Phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab.92(9), 3466–3469 (2007).
   PubMed Web of Science ®Google Scholar
• You YN, Lakhani V, Wells SA Jr. New directions in the treatment of thyroid cancer. J. Am. Coll. Surg.205(Suppl.4), S45–S48 (2007).
   Google Scholar
• Wells SA, Gosnell, JE, Gagel RF et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label Phase II trial. ASCO Annual Meeting Proceedings Part 1. J. Clin. Oncol.25(Suppl.18), (2007) (Abstract 6018).
   Google Scholar
• Sherman SI, Angelos P, Ball DW et al. Thyroid carcinoma. J. Natl Compr. Canc. Netw.5(6), 568–621 (2007).
   PubMedGoogle Scholar
• Williams D. Cancer after nuclear fallout, lessons from the Chernobyl accident. Nat. Rev. Cancer2(7), 543–549 (2002).
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr. Relat Cancer.12(2), 245–262 (2005).
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T et al. BAY 43–9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst.98(5), 326–334 (2006).
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Guida T, Anaganti S et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene23(36), 6056–6063 (2004).
   PubMed Web of Science ®Google Scholar
• Kober F, Hermann M, Handler A, Krotia G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. ASCO Annual Meeting Proceedings Part 1. J. Clin. Oncol.25(Suppl.18), (2007) (Abstract 14065).
   Google Scholar
• Mitsiades CS, McMillin D, Kotoula V et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.J. Clin. Endocrinol. Metab.91(10), 4013–4021 (2006).
   PubMedGoogle Scholar
• Cerchia L, Duconge F, Pestourie C et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol.3(4), E123 (2005).
   PubMed Web of Science ®Google Scholar
• Mauro MJ. Defining and managing imatinib resistance. Hematology1, 219–225 (2006).
   Google Scholar
• Cerchia L, Libri D, Carlomagno MS, De F. The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret. Biochem J.372(Part 3), 897–903 (2003).
   PubMedGoogle Scholar
• Drosten M, Stiewe T, Putzer BM. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther.14(10), 971–982 (2003).
   PubMed Web of Science ®Google Scholar
• Plosker GL, Keam SJ. Trastuzumab, a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs66(4), 449–475 (2006).
   PubMed Web of Science ®Google Scholar
• Yano L, Shimura M, Taniguchi M et al. Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase. Hum. Gene Ther.11(7), 995–1004 (2000).
   PubMedGoogle Scholar
• Salvatore G, Nagata S, Billaud M, Santoro M, Vecchio G, Pastan I. Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase. Biochem. Biophys. Res. Commun.294(4), 813–817 (2002).
   PubMedGoogle Scholar
• Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor α and chemotherapeutic drugs. Ann. NY Acad. Sci.1028, 104–112 (2004).
   PubMed Web of Science ®Google Scholar
• Chow LQ, Eckhardt SG. Sunitinib, from rational design to clinical efficacy. J. Clin. Oncol.25(7), 884–896 (2007).
   PubMed Web of Science ®Google Scholar
• Salgia R, Hong DS, Camacho LH et al. A Phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients with advanced malignancies. ASCO Annual Meeting Proceedings Part 1. J. Clin. Oncol.25(Suppl.18), (2007) (Abstract 14031).
   Google Scholar
• Sherman SI, Schlumberger MJ, Droz J et al. Initial results from a Phase II trial of motesnab diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). ASCO Annual Meeting Proceedings Part 1. J. Clin. Oncol.25(Suppl.18), (2007) (Abstract 6017).
   Google Scholar
• Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol.25(17), 2369–2376 (2007).
   PubMed Web of Science ®Google Scholar
• Pennell NA, Daniels GH, Haddad RI et al. A Phase II study of gefitinib in patients with advanced thyroid cancer. ASCO Annual Meeting Proceedings Part 1. J. Clin. Oncol.25(Suppl.18), (2007) (Abstract 6020).
   Google Scholar
• Salnikov AV, Heldin NE, Stuhr LB et al. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int. J. Cancer119(12), 2795–2802 (2006).
   PubMedGoogle Scholar
• Cohen EE, Vokes EE, Rosen LS et al. A Phase II study of axitinib (AG-013736 [AG] in patients with advanced thyroid cancers. ASCO Annual Meeting Proceedings Part 1. J. Clin Oncol.25(Suppl.18), (Abstract 6008) (2007).
   Google Scholar
• Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J. Nucl. Med.44(1), 1–6 (2003).
   PubMed Web of Science ®Google Scholar
• Xiao L, Lu X, Ruden DM. Effectiveness of hsp90 inhibitors as anti-cancer drugs. Mini Rev. Med. Chem.6(10), 1137–1143 (2006).
   PubMed Web of Science ®Google Scholar
• Vaishampayan UN, Sausville EA, Horiba MN et al. Phase I trial of intravenous 17-allylaminogeldanamycin (A) and oral sorafenib (B) in pretreated advanced malignancy: plasma Hsp90 induction correlates with clinical benefit. J. Clin. Oncol.25(Suppl.18), (2007) (Abstract 3531).
   Google Scholar
• Murgo AJ, Kummar S, Gardner ER et al. Phase I trial of 17-dimethylaminoethylamino-17–demethoxygeldanamycin (17-DMAG) administered twice weekly. J. Clin. Oncol.25(Suppl.18), (2007) (Abstract 3566).
   PubMedGoogle Scholar
• Chatal JF, Campion L, Kraeber-Bodere F et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy, a collaborative study with the French Endocrine Tumor Group. J. Clin Oncol.24(11), 1705–1711 (2006).
   PubMed Web of Science ®Google Scholar